Loading
Palacebo / Alzheimer Disease (AD) / Nicotinamide Riboside (NR) · Phase 2 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 2 trial of nicotinamide riboside (a NAD+ precursor) versus placebo for early Alzheimer disease, with a 24-month treatment period and disease severity (CDR) as the primary endpoint. No results have been posted to the registry, and recruitment has not yet begun. The trial aims to address whether oral NR slows AD progression and characterize its safety profile.
Phase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Alzheimer Disease (AD); age from 50 Years; to 85 Years. Intervention: Nicotinamide Riboside (NR). Compared with: Placebo — Placebo Comparator. n = 270. 2 sites: Norway.
This is a planned Phase 2 trial of nicotinamide riboside (a NAD+ precursor) versus placebo for early Alzheimer disease, with a 24-month treatment period and disease severity (CDR) as the primary endpoint. No results have been posted to the registry, and recruitment has not yet begun. The trial aims to address whether oral NR slows AD progression and characterize its safety profile.
This is a registry record with no reported results; outcome data, efficacy, safety findings, and enrollment status are not available.
If completed and positive, this trial would provide Phase 2 evidence for a novel, orally bioavailable disease-modifying approach to AD. Results are not yet available; clinicians should monitor for published outcomes.
This is a Phase 2 clinical trial registration with no reported results; the study is not yet recruiting and outcome data are not available in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
If completed and positive, this trial would provide Phase 2 evidence for a novel, orally bioavailable disease-modifying approach to AD. Results are not yet available; clinicians should monitor for published outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07741071). This is a study registration, not published results. Lead sponsor: Haukeland University Hospital. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 270 participants (ESTIMATED). Conditions: Alzheimer Disease (AD). Interventions: DIETARY_SUPPLEMENT: Nicotinamide Riboside (NR); OTHER: Palacebo. Primary outcome measures: Disease severity assessed by the Clinical Dementia Rating scale (CDR) sum of boxes. , From baseline to the end of treatment at 104 weeks.. Brief summary: The goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are: * Does drug nicotinamide riboside slow the progression of Alzheimer disease as measured by the Clinical Dementia Rating scale. * What medical problems do participants have when taking drug nicotinamide riboside? Researchers will compare drug nicotinamide riboside to a placebo (a look-alike substance that contains no drug) to see if nicotinamide riboside works to treat early Alzheimer disease. Participants will: * Take drug nicotinamide ribosie or a placebo every day for 24 months * Visit the clinic once every 26 weeks for checkups and tests
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.